scholarly journals Growth Hormone Treatment: First Results of the Partnership Program for the Establishment of a Growth Center at the University Clinic of Pediatrics –Pleven

2021 ◽  
Vol 14 (1) ◽  
pp. 62-69
Author(s):  
Irina B. Halvadzhiyan
Keyword(s):  
Growth Hormone ◽  
Hormone Treatment ◽  
University Hospital ◽  
Clinical Settings ◽  
Growth Disorders ◽  
Bone Maturation ◽  
Average Growth ◽  
First Results ◽  
Growth Center ◽  
The University

Summary In March 2018, in the Clinic of Pediatrics of the University Hospital “G. Stranski ”- Pleven, we have created a Center for diagnosing and treating children with growth disorders, in active collaboration with an established expert center. During the study, 53 children with height <-2 SDS were referred to the newly established Growth Center. The diagnoses of children receiving treatment with growth hormone (GH) were made in clinical settings based on the history, physical status, auxological assessment, imaging studies, basal and stimulated hormone tests, genetic tests. The children‘s mean age was 9.7 ± 4.5 years, with a significant gender difference (p>0.05), living mainly in cities. For 18 months, we treated a total of 11 children (54.5% male) with an average age at the start of GH therapy of 8.1 ± 4.4 years and an average growth velocity of 10.3 ± 7.7 cm/year. Treatment with GH was introduced in Pleven after successfully establishing the Growth Center in the Clinic of Pediatrics. The first results showed a significant increase in the number of diagnosed and treated children whose follow-up we found an acceleration in growth and bone maturation, positive body composition changes, and lack of side effects from the treatment.

Growth Hormone Treatment for Short Stature in the USA, Germany and France: 15 Years of Surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS)

2018 ◽  
Vol 90 (3) ◽  
pp. 169-180 ◽  
Author(s):  
Roland Pfäffle ◽  
Christof Land ◽  
Eckhard Schönau ◽  
Paul-Martin Holterhus ◽  
Judith L. Ross ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Standard Deviation Score ◽  
Measurement Data ◽  
International Study ◽  
Hormone Treatment ◽  
Height Velocity ◽  
Growth Disorders ◽  
Gh Treatment ◽  
The Usa

Background/Aims: To describe characteristics, auxological outcomes and safety in paediatric patients with growth disorders treated with growth hormone (GH), for cohorts from the USA, Germany and France enrolled in GeNeSIS, a post-authorisation surveillance programme. Methods: Diagnosis and biochemical measurement data were based on reporting from, and GH treatment was initiated at the discretion of, treating physicians. Auxological outcomes during the first 4 years of GH treatment and at near-adult height (NAH) were analysed. Serious and treatment-emergent adverse events were described. Results: Children in the USA (n = 9,810), Germany (n = 2,682) and France (n = 1,667) received GH (dose varied between countries), most commonly for GH deficiency. Across diagnostic groups and countries, mean height velocity standard deviation score (SDS) was > 0 and height SDS increased from baseline during the first 4 years of treatment, with greatest improvements during year 1. Most children achieved NAH within the normal range (height SDS >−2). No new or unexpected safety concerns were noted. Conclusion: GH treatment improved growth indices to a similar extent for patients in all three countries despite variations in GH doses. Data from these three countries, which together contributed > 60% of patients to GeNeSIS, indicated no new safety signals and the benefit-risk profile of GH remains unchanged.

scholarly journals Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International Study

2017 ◽  
Vol 102 (9) ◽  
pp. 3195-3205 ◽  
Author(s):  
Charmian A Quigley ◽  
Christopher J Child ◽  
Alan G Zimmermann ◽  
Ron G Rosenfeld ◽  
Leslie L Robison ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Turner Syndrome ◽  
International Study ◽  
Hormone Treatment ◽  
Idiopathic Short Stature ◽  
Growth Disorders ◽  
Gh Treatment ◽  
Increased Risk ◽  
History Of

Abstract Context Although pediatric growth hormone (GH) treatment is generally considered safe for approved indications, concerns have been raised regarding potential for increased risk of mortality in adults treated with GH during childhood. Objective To assess mortality in children receiving GH. Design Prospective, multinational, observational study. Setting Eight hundred twenty-seven study sites in 30 countries. Patients Children with growth disorders. Interventions GH treatment during childhood. Main Outcome Measure Standardized mortality ratios (SMRs) and 95% confidence intervals (CIs) using age- and sex-specific rates from the general population. Results Among 9504 GH-treated patients followed for ≥4 years (67,163 person-years of follow-up), 42 deaths were reported (SMR, 0.77; 95% CI, 0.56 to 1.05). SMR was significantly elevated in patients with history of malignant neoplasia (6.97; 95% CI, 3.81 to 11.69) and borderline elevated for those with other serious non–GH-deficient conditions (2.47; 95% CI, 0.99-5.09). SMRs were not elevated for children with history of benign neoplasia (1.44; 95% CI, 0.17 to 5.20), idiopathic GHD (0.11; 95% CI, 0.02 to 0.33), idiopathic short stature (0.20; 95% CI, 0.01 to 1.10), short stature associated with small for gestational age (SGA) birth (0.66; 95% CI, 0.08 to 2.37), Turner syndrome (0.51; 95% CI, 0.06 to 1.83), or short stature homeobox-containing (SHOX) gene deficiency (0.83; 95% CI, 0.02 to 4.65). Conclusions No significant increases in mortality were observed for GH-treated children with idiopathic GHD, idiopathic short stature, born SGA, Turner syndrome, SHOX deficiency, or history of benign neoplasia. Mortality was elevated for children with prior malignancy and those with underlying serious non–GH-deficient medical conditions.

Benefits of using telemedicine and first results in Bosnia and Herzegovina

1998 ◽  
Vol 4 (1_suppl) ◽  
pp. 91-93 ◽  
Author(s):  
Nurija Bilalović ◽  
Carlo Paties ◽  
Andreas Mason
Keyword(s):  
Bosnia And Herzegovina ◽  
University Hospital ◽  
Small Country ◽  
First Results ◽  
Time Required ◽  
The University ◽  
Consultation Time

In October 1996 the Institute of Pathology with the Radiology and Ophthalmology Clinic of the university hospital of Sarajevo joined the experimental telemedicine project SHARED. Two months after the project began, dermatology, paediatrics and haematology were also included. During the first phase we had 40 teleconsultations that showed us the benefits of using telemedicine. Our opinions and the opinions of the pathologist in Milan were similar for most of the biopsies (78%). The total time required for the consultation for the first 40 cases was 372 min, or 9.3 min each, on average. The longest consultation time was 25 min. The largest number of images was 44 per case, the smallest four. Because of problems of infrastructure and lack of experts, telemedicine will be important to a small country like Bosnia and Herzegovina.

scholarly journals Hyperprolactinemia in Acromegaly is Related to Prolactin Secretion by Somatolactotroph Tumours

2020 ◽  
Vol 52 (09) ◽  
pp. 647-653
Author(s):  
Delphine Van Laethem ◽  
Alex Michotte ◽  
Wilfried Cools ◽  
Brigitte Velkeniers ◽  
David Unuane ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Prolactin Level ◽  
Patient Characteristics ◽  
Tumour Volume ◽  
Prolactin Secretion ◽  
University Hospital ◽  
Serum Prolactin ◽  
Ki 67 ◽  
Adenoma Tissue ◽  
The University

AbstractThe aim of this study is to assess differences in patient characteristics, tumour characteristics and hormone levels between acromegalic patients with and without hyperprolactinemia. 44 patients of the University Hospital of Brussels, Belgium with acromegaly who were diagnosed between January 2007 and July 2018 were included in this study. Nineteen patients were classified in the hyperprolactinemia group and 25 patients were classified in the normoprolactinemia group. No significant differences between acromegalic patients with and without hyperprolactinemia were found in age at diagnosis, gender, presence of hyperprolactinemia symptoms, insulin-like growth factor 1, growth hormone and testosterone levels, tumour volume, tumour invasiveness, immunohistochemistry of growth hormone and prolactin, Ki-67 index and mitotic index. However, for a cut-off of 10% of prolactin-positive cells, there was a trend towards a higher percentage of prolactin-positive tumours in hyperprolactinemia patients (p=0.054) and higher mean prolactin level in case of positive prolactin immunostaining (p=0.007)). In our study there were no differences in characteristics between acromegaly patients with hyper- and normoprolactinemia. An association between the serum prolactin level and the positivity of prolactin immunohistochemistry of the adenoma tissue was found. The absence of a difference in tumour volume between patients with hyper- and normoprolactinemia suggests that the hyperprolactinemia is likely to be caused by the co-secretion of growth hormone and prolactin by the tumour. Finally, for the first time, the cut-off of 10% of prolactin cells was validated for the diagnosis of somatolactotroph tumours in acromegaly.

Growth hormone treatment of rats with chronic diverting colostomy. Differential response on proximal functioning and distal atrophic colon

1994 ◽  
Vol 130 (5) ◽  
pp. 508-514 ◽  
Author(s):  
P Kissmeyer-Nielsen ◽  
H Christensen ◽  
S Laurberg
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Muscularis Propria ◽  
Hormone Treatment ◽  
Differential Response ◽  
Collagen Content ◽  
University Hospital ◽  
Female Rats ◽  
Trophic Effect ◽  
Diverting Colostomy

Kissmeyer-Nielsen P, Christensen H, Laurberg S. Growth hormone treatment of rats with chronic diverting colostomy. Differential response on proximal functioning and distal atrophic colon. Eur I Endocrinol 1994;130:508–14. ISSN 0804–4643 Diversion of colon from the fecal stream leads to profound intestinal atrophy. After diverting colostomy for 4 weeks, female rats were treated with biosynthetic human growth hormone (b-hGH; 2.0 mg.kg−1 body wt.day−1) in order to investigate whether b-hGH could reverse atrophic changes in distal colon, with special reference to changes in morphometric composition, collagen content and biomechanical properties. Biosynthetic hGH treatment for 28 days stimulated growth of the muscularis propria of the defunctioned, atrophic colon (p < 0.05), whereas the mucosal atrophy was unaffected by the treatment. In colon proximal to the colostomy, however, b-hGH increased the colonic wet weight (p < 0.01), defatted dry weight (p < 0.005) and the collagen content (p < 0.05). Morphometric analysis showed that the growth increase was localized to the mucosa and the muscularis propria. In conclusion, fecal diversion alters the response of b-hGH treatment and indicates that the trophic effect of growth hormone on colonic mucosa is dependent on fecal bulk passage, whereas the trophic effect on muscularis propria is fully retained when colon is deprived of luminal nutrients. Peter Kissmeyer-Nielsen, Surgical Research Unit, Department of Surgery L, Amtssygehuset, University Hospital of Aarhus, DK-8000 Aarhus C, Denmark

scholarly journals Growth Hormone Treatment Adherence in Prepubertal and Pubertal Children with Different Growth Disorders

2013 ◽  
Vol 80 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Klaus Hartmann ◽  
Jochen Ittner ◽  
Elke Müller-Rossberg ◽  
Eckhard Schönau ◽  
Roger Stephan ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Treatment Adherence ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Growth Disorders
Sign in / Sign up

Export Citation Format

Share Document